A citation-based method for searching scientific literature

Raymond R Townsend, Israel Machin, Jimmy Ren, Angelina Trujillo, Masato Kawaguchi, Ujjwala Vijapurkar, Chandrasekharrao V Damaraju, Michael Pfeifer. J Clin Hypertens (Greenwich) 2016
Times Cited: 55







List of co-cited articles
662 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study.
J P H Wilding, E Ferrannini, V A Fonseca, W Wilpshaar, P Dhanjal, A Houzer. Diabetes Obes Metab 2013
90
9





Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Heidi Storgaard, Lise L Gluud, Cathy Bennett, Magnus F Grøndahl, Mikkel B Christensen, Filip K Knop, Tina Vilsbøll. PLoS One 2016
98
9

Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus.
Nobuya Inagaki, Shin-Ichi Harashima, Nobuko Maruyama, Yutaka Kawaguchi, Maki Goda, Hiroaki Iijima. Cardiovasc Diabetol 2016
42
11

Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.
Linong Ji, Jianhua Ma, Hongmei Li, Traci A Mansfield, Caroline L T'joen, Nayyar Iqbal, Agata Ptaszynska, James F List. Clin Ther 2014
108
9

Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes.
Javad Habibi, Annayya R Aroor, James R Sowers, Guanghong Jia, Melvin R Hayden, Mona Garro, Brady Barron, Eric Mayoux, R Scott Rector, Adam Whaley-Connell,[...]. Cardiovasc Diabetol 2017
108
9

Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.
Ralph A DeFronzo, Andrew Lewin, Sanjay Patel, Dacheng Liu, Renee Kaste, Hans J Woerle, Uli C Broedl. Diabetes Care 2015
198
9


Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits.
Antonius Baartscheer, Cees A Schumacher, Rob C I Wüst, Jan W T Fiolet, Ger J M Stienen, Ruben Coronel, Coert J Zuurbier. Diabetologia 2017
224
9

The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.
Meg J Jardine, Kenneth W Mahaffey, Bruce Neal, Rajiv Agarwal, George L Bakris, Barry M Brenner, Scott Bull, Christopher P Cannon, David M Charytan, Dick de Zeeuw,[...]. Am J Nephrol 2017
124
9

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.
Silvio E Inzucchi, Bernard Zinman, David Fitchett, Christoph Wanner, Ele Ferrannini, Martin Schumacher, Claudia Schmoor, Kristin Ohneberg, Odd Erik Johansen, Jyothis T George,[...]. Diabetes Care 2018
279
9

Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study.
Anna Solini, Livia Giannini, Marta Seghieri, Edoardo Vitolo, Stefano Taddei, Lorenzo Ghiadoni, Rosa Maria Bruno. Cardiovasc Diabetol 2017
130
9

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
Kenneth W Mahaffey, Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Elisa Fabbrini, Tao Sun, Qiang Li,[...]. Circulation 2018
219
9

The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity.
Ningning Wan, Asadur Rahman, Hirofumi Hitomi, Akira Nishiyama. Front Endocrinol (Lausanne) 2018
32
15

Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2.
Vance B Matthews, Rosemary H Elliot, Caroline Rudnicka, Jana Hricova, Lakshini Herat, Markus P Schlaich. J Hypertens 2017
69
9

Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension.
Robert Chilton, Ilkka Tikkanen, Uwe Hehnke, Hans J Woerle, Odd Erik Johansen. Diabetes Obes Metab 2017
20
25

Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: A randomized controlled trial.
Wenying Yang, Jianhua Ma, Yiming Li, Yanbing Li, Zhiguang Zhou, Jae Hyeon Kim, June Zhao, Agata Ptaszynska. J Diabetes 2018
22
22

Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).
Julio Rosenstock, Juan Frias, Dénes Páll, Bernard Charbonnel, Raluca Pascu, Didier Saur, Amanda Darekar, Susan Huyck, Harry Shi, Brett Lauring,[...]. Diabetes Obes Metab 2018
80
9


A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation.
Christian Ott, Agnes Jumar, Kristina Striepe, Stefanie Friedrich, Marina V Karg, Peter Bramlage, Roland E Schmieder. Cardiovasc Diabetol 2017
60
9


SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
856
9

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
9

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
Bryan Williams, Thomas M MacDonald, Steve Morant, David J Webb, Peter Sever, Gordon McInnes, Ian Ford, J Kennedy Cruickshank, Mark J Caulfield, Jackie Salsbury,[...]. Lancet 2015
495
7



Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.
Rena R Wing, Paula Bolin, Frederick L Brancati, George A Bray, Jeanne M Clark, Mace Coday, Richard S Crow, Jeffrey M Curtis, Caitlin M Egan, Mark A Espeland,[...]. N Engl J Med 2013
7




Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies.
Alan Sinclair, Bruce Bode, Stewart Harris, Ujjwala Vijapurkar, Cristiana Mayer, Albert Fung, Wayne Shaw, Keith Usiskin, Mehul Desai, Gary Meininger. BMC Endocr Disord 2014
61
7


Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes.
S Matthaei, K Bowering, K Rohwedder, J Sugg, S Parikh, E Johnsson. Diabetes Obes Metab 2015
43
9

SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.
Ele Ferrannini, Anna Solini. Nat Rev Endocrinol 2012
246
7

Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus.
Nelson B Watts, John P Bilezikian, Keith Usiskin, Robert Edwards, Mehul Desai, Gordon Law, Gary Meininger. J Clin Endocrinol Metab 2016
216
7

Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?
Jiwen Jim Liu, TaeWeon Lee, Ralph A DeFronzo. Diabetes 2012
131
7

Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.
Keith Usiskin, Irina Kline, Albert Fung, Cristiana Mayer, Gary Meininger. Postgrad Med 2014
71
7

Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study.
David Polidori, Sue Sha, Sunder Mudaliar, Theodore P Ciaraldi, Atalanta Ghosh, Nicole Vaccaro, Kristin Farrell, Paul Rothenberg, Robert R Henry. Diabetes Care 2013
177
7

Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.
Muhammad A Abdul-Ghani, Luke Norton, Ralph A Defronzo. Endocr Rev 2011
252
7

Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus.
Volker Vallon, Michael Rose, Maria Gerasimova, Joseph Satriano, Kenneth A Platt, Hermann Koepsell, Robyn Cunard, Kumar Sharma, Scott C Thomson, Timo Rieg. Am J Physiol Renal Physiol 2013
208
7

Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome.
Asadur Rahman, Wararat Kittikulsuth, Yoshihide Fujisawa, Abu Sufiun, Kazi Rafiq, Hirofumi Hitomi, Daisuke Nakano, Eisei Sohara, Shinichi Uchida, Akira Nishiyama. J Hypertens 2016
30
13

Sodium-glucose cotransporter inhibition prevents oxidative stress in the kidney of diabetic rats.
Horacio Osorio, Israel Coronel, Abraham Arellano, Ursino Pacheco, Rocío Bautista, Martha Franco, Bruno Escalante. Oxid Med Cell Longev 2012
57
7

Circadian blood pressure rhythm as a possible key target of SGLT2 inhibitors used for the treatment of Type 2 diabetes.
Kouichi Tamura, Hiromichi Wakui, Kengo Azushima, Kazushi Uneda, Satoshi Umemura. Hypertens Res 2016
8
50

A Randomized Trial of Intensive versus Standard Blood-Pressure Control.
Jackson T Wright, Jeff D Williamson, Paul K Whelton, Joni K Snyder, Kaycee M Sink, Michael V Rocco, David M Reboussin, Mahboob Rahman, Suzanne Oparil, Cora E Lewis,[...]. N Engl J Med 2015
7


Diabetes and hypertension: the bad companions.
Ele Ferrannini, William C Cushman. Lancet 2012
265
7



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.